Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2010-02-11
2011-11-01
Salimi, Ali R. (Department: 1649)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S002000, C600S410000, C600S420000
Reexamination Certificate
active
08048639
ABSTRACT:
The invention relates to methods and reagents for diagnosing and assessing the prognosis of multiple sclerosis.
REFERENCES:
patent: 5030560 (1991-07-01), Sinor et al.
patent: 6972172 (2005-12-01), Dukler et al.
patent: 7537900 (2009-05-01), Dotan et al.
patent: 7572592 (2009-08-01), Dotan et al.
patent: 7906291 (2011-03-01), Dotan et al.
patent: 2004/0077023 (2004-04-01), Dotan et al.
patent: 2004/0241763 (2004-12-01), Dotan et al.
patent: 2006/0172338 (2006-08-01), Dotan et al.
patent: 2006/0234301 (2006-10-01), Dotan et al.
patent: 02151765 (1990-06-01), None
patent: 02161357 (1990-06-01), None
patent: WO-0049412 (2000-08-01), None
patent: WO-0114881 (2001-03-01), None
patent: WO-0151207 (2001-07-01), None
patent: WO-0218950 (2002-03-01), None
patent: WO-02064556 (2002-08-01), None
patent: WO-03000733 (2003-01-01), None
patent: WO-2004015420 (2004-02-01), None
patent: 2004034031 (2004-04-01), None
patent: WO-2004077023 (2004-09-01), None
patent: WO-2006/117689 (2006-11-01), None
Freedman, “Anti-alpha-glucose-based Glycan IgM Antibodies in Patients with a Clinically Isolated Syndrome: Analyses from the Betaferon in Newly Emerging Multiple Sclerosis for Initial Treatment (BENEFIT) Study”, ECTRIMS, Aug. 27, 2009.
Dotan N. et al., “Anti-glycan antibodies as biomarkers for diagnosis and prognosis” Lupus, Basingstoke, GB, 15 (7):442-450 (2006).
Dalton et al., “Application of the new McDonald Criteria to Patients with Clinically Isolated Syndromes Suggestive of Multiple Sclerosis”,Ann. Neurol., 52:47-53 (2002).
Alberts et al. “Sugars Are Food Molecules of the Cell”, inMolecular Biology of the Cell, Garland Publishing Inc., New York & London, pp. 50-51 (1983).
Banin et al., “A Novel Linear Code® Nomenclature for Complex Carbohydrates”,Trends Glycoscience Glycotech., 14(77):127-137 (2002).
Bao, J. J., “Capillary electrophoretic immunoassays”,J. Chromatogr. B., 699:463-480 (1997).
Bergamaschi, R., “Prognostic Factors in Multiples Sclerosis”,Int. Rev. Neurobiol., 79:423-447 (2007).
Berger et al., “Antimyelin Antibodies as a Predictor of Clinically Definite Multiple Sclerosis after a First Demyelinating Event”,N. Engl. J. Med., 349(2):139-145 (2003).
Binder et al., “The role of natural antibodies in atherogenesis”,J. Lipid Res., 46:1353-1363 (2005).
Boneschi et al., “Mitoxantrone for multiple sclerosis”,Cochrane Database of Systematic Rev., 4:CD002127 (2005).
Bozzaro et al., “Monoclonal Antibodies againstDictyosteliumPlasma Membranes: their Binding to Simple Sugars”,Cell Differentiation, 17:83-94 (1985).
Brex et al., “A Longitudinal Study of Abnormalities on MRI and Disability From Multiple Sclerosis”,N. Engl. J. Med., 346 (3):158-164 (2002).
Brusaferri et al., “Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials”,J. Neurol., 247(6):435-442 (2000).
Carotenuto et al., “Conformational Analysis of a Glycosylated Human Myelin Oligodendrocyte Glycoprotein Peptide Epitope Able to Detect Antibody Response in Multiple Sclerosis”,J. Med. Chem., 44:2378-2381 (2001).
Comi et al., “Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study”,Lancet, 357(9268):1576-1582 (2001).
Confavreux et al., “Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process”,Brain, 126:770-782 (2003).
Dovio et al., “Immediate Fall of Bone Formation and Transient Increase of Bone Resorption in the Course of High-Dose, Short-Term Glucocorticoid Therapy in Young Patients with Multiple Sclerosis”,J. Clin. Endocrinol. Metab., 89(10):4923-4928 (2004).
Durelli et al., “MRI activity and neutralising antibody as predictors of response to interferon beta treatment in multiple sclerosis”,J. Neurol. Neurosurg. Psychiatry., 79:646-651 (2008).
Felici et al., “Phage-Displayed Peptides as Tools for Characterization of Human Sera”,Meth. Enzymol., 267:116-129 (1996).
Fisniku et al., “Disability and T2MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis”,Brain, 131:808-817 (2008).
Freedman et al., “Anti-α-glucose-based glycan IgM antibodies predict relapse activity in multiple sclerosis after the first neurological event”,Multiple Sclerosis, 15:422-430 (2009).
Freedman et al., “Recommended Standard of Cerebrospinal Fluid Analysis in the Diagnosis of Multiple Sclerosis”,Arch. Neurol., 62:865-870 (2005).
Gonsette, R.E., “Compared benefit of approved and experimental immunosuppressive therapeutic approaches in multiple sclerosis”,Exp. Opin. Pharmacother., 8(8):1103-1116 (2007).
Gyorgy et al., “Natural autoantibodies reactive with glycosaminoglycans in rheumatoid arthritis”,Arthritis Res. Ther., 10(5):1-12 (2008).
Holme et al., “Structural Studies on the O-Specific Side-Chains of the Cell-Wall Lipopolysaccharide fromSalmonella typhimurium395 MS”,Carbohydr. Res., 8:43-55 (1968).
Hou et al., “Development of Peptide Mimotopes of Lipooligosaccharide from NontypeableHaemophilus influenzaeas Vaccine Candidates”,J. Immunol., 170:4373-4379 (2003).
International Search Report for PCT/IB2003/03878, mailed Jan. 9, 2004.
International Search Report for PCT/IB2006/001666, mailed Nov. 8, 2006.
Jacobs et al., “Correlation of Clinical, Magnetic Resonance Imaging, and Cerebrospinal Fluid Findings in Optic Neuritis”,Ann. Neurol., 41(3):392-398 (1997).
Jacobs et al., “Intramuscular Interferon Beta-1a Therapy Initiated During a First Demyelinating Event in Multiple Sclerosis”,N. Engl. J. Med., 343(13):898-904 (2000).
Johnson, K. P., “Control of multiple sclerosis relapses with immunomodulating agents”,J. Neurol. Sci., 256(Suppl. 1):S23-S28 (2007).
Kappos et al., “Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study”,Lancet, 370(9585):389-397 (2007).
Kuhle et al., “Lack of Association between Antimyelin Antibodies and Progression to Multiple Sclerosis”,N. Engl. J. Med., 356:371-378 (2007).
Kurtzke, J. F., Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS),Neurol., 33(11):1444-1452 (1983).
Leary et al., “Primary Progressive Multiple Sclerosis Current and Future Treatment Options”,CNS Drugs, 19(5):369-376 (2005).
Lolli et al., “An N-glucosylated peptide detecting disease-specific autoantibodies, biomarkers of multiple sclerosis”,Proc. Natl. Acad. Sci. U.S.A., 102(29):10273-10278 (2005).
Lolli et al., “The glycopeptides CSF114(Glc) detects serum antibodies in multiple sclerosis”,J. Neuroimmunol., 167:131-137 (2005).
Mandrioli et al., “A multifactorial prognostic index in multiple sclerosis. Cerebrospinal fluid IgM oligoclonal bands and clinical features to predict the evolution of the disease”,J. Neurol., 255:1023-1031 (2008).
Martinelli et al., “Mitoxantrone for multiple sclerosis”,Cochrane Database System Reviews, (4):CD002127 (2005).
Matsuda, et al., “Antibody Response to Haptenic Sugar Antigen: Immunodominancy of Protein-Bound Lactose Formed by Amino-Carbonyl Reaction”,Mol. Immun., 24(5):421-425 (1987).
Mazzucco et al., “A Synthetic Glycopeptide of Human Myelin Oligodendrocyte Glycoprotein to Detect Antibody Responses in Multiple Sclerosis and Other Neurological Diseases”,Bioorg. Med. Chem. Lett., 9:167-172 (1999).
McDonald et al., “Recommended Diagnostic Criteria for Multiple Sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis”,Ann. Neurol., 50(1):121-127 (2001).
Miller et al., “Differential diagnosis of susp
Dotan Nir
Dukler Avinoam
Yarden Jennifer
Beattie Ingrid A.
Elrifi Ivor R.
Glycominds Ltd.
Gucker Stephen
Mintz Levin Cohn Ferris Glovsky and Popeo P.C.
LandOfFree
Method for evaluating risk in multiple sclerosis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for evaluating risk in multiple sclerosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for evaluating risk in multiple sclerosis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4270299